similtaneously Dextran 75 Dosage Form: injection, powder, lyophilized, for solution Overview Side Effects Professional Interactions Reviews More Support Group Q & A Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here. Dextran 75 Dear Medical Professional, Per your order, we have compounded Dextran 75 as a lyophilized powder for injection. The characteristics of this preparation are as follows: Slideshow 10 Common Symptoms That Should Never Be Ignored Dextran 75 Description AnazaoHealth supplies compounded Dextran 75 for the preparation of Tc-99m Dextran 75. Each reaction vial contains 10 mg of Dextran 75, 0.30mg of stannous chloride, 0.73 mg Sodium Citrate and 1 mg of dextrose (lyophilized mixture, under nitrogen atmosphere), per unit dose vial. Mechanism of Action Dextran, when labeled with technetium Tc99m and given intravenously, is distributed throughout the body in much the same way as the patient s serum, and serves as a suitable tracer with which to transiently image the vascular compartment Indications and Usage for Dextran 75 Technetium Tc99m Dextran by intravenous administration is indicated as a cardiac blood pool imaging agent and as an adjunct in the diagnosis of pericardial effusion, ventricular aneurysm, or GI Bleed Dextran 75 Dosage and Administration To prepare injection, up to 40 mCi of an oxidant-free sodium pertechnetate Tc 99m solution is aseptically injected into the vial, minimum volume 1ml, mix gently and let Dextran dissolve completely for 10 minutes Storage and Handling Injection should be administered within 6 hours after preparation. Before and after reconstitution- Store at room temperature PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Figure 1 Dextran 75 Dextran 75 injection, powder, lyophilized, for solution Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:51808-210 Route of Administration INTRAVENOUS DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength Dextran 75 (Dextran 75) Dextran 75 10 mg Inactive Ingredients Ingredient Name Strength STANNOUS CHLORIDE 0.3 mg ANHYDROUS DEXTROSE 1 mg SODIUM CITRATE 0.73 mg Product Characteristics Color Score no score Shape Size Flavor Imprint Code Contains Packaging # Item Code Package Description 1 NDC:51808-210-01 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION (VIAL) in 1 KIT Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date Unapproved drug other 07/01/2012 Labeler - AnazaoHealth Corporation (011038762) Establishment Name Address ID/FEI Operations AnazaoHealth Corporation 011038762 MANUFACTURE(51808-210) Revised: 07/2012 AnazaoHealth Corporation Next Interactions Print this page Add to My Med List More about dextran, high molecular weight Side Effects Drug Interactions Support Group En Español 0 Reviews Add your own review/rating Drug class: plasma expanders Consumer resources Dextran high molecular weight Related treatment guides Bleeding Disorder FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug WADA Class Anti-Doping Classification Drug Class Plasma expanders Related Drugs plasma expanders Albutein , Dextran 40 , albumin human , Buminate , Dextran 70 6% in 5% Dextrose , hydroxyethyl starch Bleeding Disorder tranexamic acid , Zoladex , goserelin , Cyklokapron , Dextran 70 6% in 5% Dextrose , Trasylol , More... Dextran, high molecular weight Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first! contemporary
a devoted Dextran 75 inability
EmoticonEmoticon